DNA and the Constitution
By Editorial,
The New York Times
| 02. 24. 2013
On Tuesday, the Supreme Court is scheduled to hear argument about whether it is constitutional for a state to collect DNA from people charged with violent crimes but not yet convicted. Last April, the Maryland Court of Appeals ruled that a state law authorizing such collection violated the Fourth Amendment’s prohibition against unreasonable searches and seizures.
Maryland law enforcement officials were allowed to continue collecting DNA samples, however, through an order last July by Chief Justice John Roberts Jr. He said there was a “fair prospect” that the Supreme Court would reverse the Maryland decision, which conflicts with rulings of the Virginia Supreme Court and of the United States Courts of Appeals for the Third and the Ninth Circuits on similar statutes in other states. But the justices should uphold the Maryland court’s ruling, thus calling into question those other rulings. The Maryland law clearly contravenes the Fourth Amendment.
The case involves the collection of DNA from Alonzo Jay King Jr. after his arrest on assault charges in 2009. His DNA profile matched evidence from a rape in 2003, and...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...